A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
NCT00000857
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
65
Enrollment
NIH
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Interleukin-12
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)